StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
24
This year
1
Publishing Date
2024 - 01 - 29
1
2023 - 10 - 23
1
2023 - 09 - 11
2
2023 - 08 - 31
1
2023 - 07 - 27
2
2023 - 06 - 05
2
2023 - 03 - 06
1
2022 - 12 - 07
2
2022 - 08 - 15
1
2022 - 08 - 12
2
2022 - 07 - 25
2
2022 - 05 - 05
2
2022 - 04 - 19
1
2022 - 02 - 21
1
2022 - 01 - 17
1
2021 - 12 - 23
1
2021 - 12 - 09
1
Sector
Health technology
24
Tags
Agreement
12
Alliances
24
America
28
Antibody
19
Astrazeneca
16
Biotech
28
Breast
11
Breast cancer
13
Cancer
144
Cell
14
Clinical-trials-phase-iii
16
Collaboration
14
Covid-19
8
Diabetes
16
Diagnostic
10
Diagnostics
11
Disease
34
Drug
70
Drug delivery
12
Enhertu
24
Europe
11
Expected
13
Fda
9
Financial
10
Financial results
9
Global
108
Granted
8
Growing
24
Growth
120
Health
9
Her2
27
Her2-
18
Immunotherapy
10
Iot
8
Key
9
License
16
Liver
18
Lung
24
Lung cancer
10
Market
267
Metastatic breast cancer
11
N/a
516
Partnership
8
People
10
Pharma
10
Positive
13
Reach
20
Report
95
Research
73
Respiratory
12
Results
30
Review
11
Set
16
System
9
Technology
10
Therapeutics
71
Therapy
32
Treatment
46
Trial
52
Vaccine
29
Entities
Astrazeneca plc
24
Symbols
ALXO
1
AZN
24
BOLT
1
TMO
1
Exchanges
Nasdaq
24
Crawled Date
2024 - 01 - 29
1
2023 - 10 - 23
1
2023 - 09 - 11
2
2023 - 08 - 31
1
2023 - 07 - 27
2
2023 - 06 - 05
2
2023 - 03 - 06
1
2022 - 12 - 07
2
2022 - 08 - 15
1
2022 - 08 - 12
2
2022 - 07 - 25
2
2022 - 05 - 05
2
2022 - 04 - 19
1
2022 - 02 - 21
1
2022 - 01 - 17
1
2021 - 12 - 23
1
2021 - 12 - 09
1
Crawled Time
08:00
1
09:00
3
10:00
2
11:00
4
12:00
4
13:00
1
14:00
3
14:30
1
15:00
1
17:00
1
19:00
2
20:00
1
Source
www.biospace.com
24
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Enhertu
symbols :
AZN
save search
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
Published:
2024-01-29
(Crawled : 11:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
6.11%
|
O:
0.24%
H:
0.07%
C:
-0.1%
enhertu
her2
granted
review
tumors
positive
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Published:
2023-10-23
(Crawled : 20:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
11.55%
|
O:
-1.57%
H:
1.06%
C:
0.36%
enhertu
her2
tumors
trial
phase 2
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
Published:
2023-09-11
(Crawled : 13:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
4.37%
|
O:
-3.31%
H:
1.02%
C:
0.97%
enhertu
lung
cancer
tumor
trial
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
Published:
2023-09-11
(Crawled : 11:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
4.37%
|
O:
-3.31%
H:
1.02%
C:
0.97%
enhertu
lung
her2
cancer
tumor
trial
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers
Published:
2023-08-31
(Crawled : 14:30)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
3.4%
|
O:
0.19%
H:
0.0%
C:
-1.7%
enhertu
her2
granted
therapy
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
Published:
2023-07-27
(Crawled : 12:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
4.03%
|
O:
0.42%
H:
0.55%
C:
-0.86%
enhertu
tumors
trial
ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Published:
2023-07-27
(Crawled : 10:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
4.03%
|
O:
0.42%
H:
0.55%
C:
-0.86%
enhertu
her2
tumors
trial
ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors
Published:
2023-06-05
(Crawled : 19:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
-1.91%
|
O:
0.39%
H:
0.78%
C:
0.45%
enhertu
her2
tumors
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
Published:
2023-06-05
(Crawled : 17:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
-1.91%
|
O:
0.39%
H:
0.78%
C:
0.45%
enhertu
tumors
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
Published:
2023-03-06
(Crawled : 14:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
9.2%
|
O:
-1.01%
H:
0.59%
C:
0.03%
enhertu
tumor
trial
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
Published:
2022-12-07
(Crawled : 15:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
3.85%
|
O:
0.45%
H:
0.64%
C:
-0.03%
enhertu
risk
breast
positive
cancer
her2-
her2
metastatic breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
Published:
2022-12-07
(Crawled : 14:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
3.85%
|
O:
0.45%
H:
0.64%
C:
-0.03%
enhertu
risk
breast
cancer
her2-
her2
metastatic breast cancer
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
Published:
2022-08-15
(Crawled : 09:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
6.84%
|
O:
0.92%
H:
0.22%
C:
-0.65%
enhertu
treatment
disease
trial
positive
cancer
her2-
her2
metastatic breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
Published:
2022-08-12
(Crawled : 12:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
10.13%
|
O:
0.09%
H:
3.83%
C:
2.98%
enhertu
lung
approved
therapy
cancer
her2-
her2
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published:
2022-08-12
(Crawled : 08:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
10.13%
|
O:
0.09%
H:
3.83%
C:
2.98%
enhertu
lung
approved
therapy
cancer
her2-
her2
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
Published:
2022-07-25
(Crawled : 12:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
9.12%
|
O:
1.43%
H:
0.39%
C:
-0.04%
enhertu
granted
review
cancer
her2-
her2
metastatic breast cancer
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer
Published:
2022-07-25
(Crawled : 11:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
9.12%
|
O:
1.43%
H:
0.39%
C:
-0.04%
enhertu
granted
review
cancer
her2-
her2
metastatic breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Published:
2022-05-05
(Crawled : 12:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
6.84%
|
O:
-1.35%
H:
0.4%
C:
-1.2%
enhertu
approved
cancer
breast cancer
her2-
her2
metastatic breast cancer
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published:
2022-05-05
(Crawled : 10:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
6.84%
|
O:
-1.35%
H:
0.4%
C:
-1.2%
enhertu
approved
positive
cancer
breast cancer
her2-
her2
metastatic breast cancer
ENHERTU® Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published:
2022-04-19
(Crawled : 11:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
3.38%
|
O:
-0.44%
H:
0.66%
C:
-0.42%
enhertu
granted
review
cancer
her2-
her2
← Previous
1
2
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.